Goldman Sachs
CCCC icon

Goldman Sachs’s C4 Therapeutics CCCC Stock Holding History

Goldman Sachs’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Buy
3,530,991
+1,143,613
+48% +$3.91M ﹤0.01% 2821
2026
Q1 		$6.28M Buy
2,387,378
+1,298,358
+119% +$3.06M ﹤0.01% 3477
2025
Q4 		$2.08M Buy
1,089,020
+629,127
+137% +$1.49M ﹤0.01% 4553
2025
Q3 		$1.02M Sell
459,893
-420,365
-48% -$1.01M ﹤0.01% 5001
2025
Q2 		$1.26M Buy
880,258
+257,538
+41% +$375K ﹤0.01% 4525
2025
Q1 		$996K Buy
622,720
+49,065
+9% +$146K ﹤0.01% 4692
2024
Q4 		$2.07M Buy
573,655
+67,803
+13% +$337K ﹤0.01% 4253
2024
Q3 		$2.88M Sell
505,852
-231,983
-31% -$1.4M ﹤0.01% 3827
2024
Q2 		$3.41M Sell
737,835
-543,407
-42% -$3.24M ﹤0.01% 3507
2024
Q1 		$10.5M Buy
1,281,242
+1,167,729
+1,029% +$9.05M ﹤0.01% 2426
2023
Q4 		$641K Sell
113,513
-105,210
-48% -$240K ﹤0.01% 4619
2023
Q3 		$407K Sell
218,723
-11,843
-5% -$36.1K ﹤0.01% 4746
2023
Q2 		$634K Sell
230,566
-115,017
-33% -$370K ﹤0.01% 4612
2023
Q1 		$1.09M Buy
345,583
+61,631
+22% +$363K ﹤0.01% 4329
2022
Q4 		$1.68M Sell
283,952
-136,891
-33% -$1.14M ﹤0.01% 4072
2022
Q3 		$3.69M Buy
420,843
+289,119
+219% +$3M ﹤0.01% 3419
2022
Q2 		$993K Buy
131,724
+11,935
+10% +$105K ﹤0.01% 4608
2022
Q1 		$2.91M Sell
119,789
-105,059
-47% -$2.55M ﹤0.01% 3900
2021
Q4 		$7.24M Sell
224,848
-39,116
-15% -$1.55M ﹤0.01% 3059
2021
Q3 		$11.8M Buy
263,964
+33,001
+14% +$1.41M ﹤0.01% 2561
2021
Q2 		$8.74M Buy
+230,963
New +$8.27M ﹤0.01% 2820
2021
Q1 		– Sell
-12,624
Closed -$418K – 6099
2020
Q4 		$418K Buy
+12,624
New +$366K ﹤0.01% 4710

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Goldman Sachs's CCCC Position: Q2 2026 in Review

Goldman Sachs increased its C4 Therapeutics (CCCC) stake by 48% in Q2 2026, buying an estimated $3.91M and bringing the position to 3,530,991 shares worth $16.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2821.

Goldman Sachs first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Goldman Sachs held 3,530,991 shares of C4 Therapeutics worth $16.5M as of Q2 2026.
  • Goldman Sachs bought 1,143,613 C4 Therapeutics shares in Q2 2026, an estimated $3.91M.
  • C4 Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2821 holding.
  • Goldman Sachs first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.